Read the reviews
Review
The Lancet Neurology, Volume 8, Issue 12, Page 1092, November 2009
doi:10.1016/S1474-4422(09)70318-7
The nuts and bolts of neuroscience trials
Craig Anderson
'Clinical trials are conceptually simple forms of research: take a group of individuals and randomly allocate them
to one (or sometimes more) different exposures, one of which is usually a control, and follow them up to detect differences
between the groups in one key, and several other important, outcomes. This procedure allows rejection of a null hypothesis
regarding the likely effects of the intervention. Relevant to this endeavour is ensuring appropriate study design, funding, management, ...
Clinical Trials in the Neurosciences is a welcomed addition to the scientific literature because this text provides a broad overview of an increasingly important
area through a collection of topical chapters written by experienced, albeit predominantly US-based, researchers. ...
This book will hopefully provide a useful guide to the inexperienced researcher who has caught the bug and wishes to pursue a career that, in part or as a whole, involves efforts
to translate knowledge regarding neuronal injury and repair from the bench into new therapies for the prevention and treatment of neurological conditions at the bedside.'
You can read this review in its entirety on the
The Lancet website
A comprehensive and practical overview
A properly designed and executed clinical trial that addresses an import question and delivers a definitive result can change the practice of medicine worldwide. This book encompasses a bench-to-bedside approach and serves as an excellent guidance for translating preclinical studies to early phase I/II and phase III trials. In the first part, the book covers preclinical science with respect to animal models of various neurological diseases, FDA requirements for preclinical studies, translation of animal to patient studies and scaling up from animal to human studies. In the second part, the design of phase I/II trials and the use of biomarkers as surrogate endpoints are discussed. With regard to phase III trials, FDA and European requirements, specific design issues, relevant clinical endpoints as well as data management and quality are examined. Topics specific to multicenter trials, such as design, recruitment of special populations, monitoring, ethical and consent issues are also covered. Finally, genetics, gene therapy, imaging and surgical devices are reviewed.
This publication is highly recommended to clinician researchers, such as neurologists, neurosurgeons, pediatric neurologists and neonatologists, who want to design and conduct clinical trials in the neuroscience, but also to nurses, research coordinators and clinical pharmacologists.
Log in to MyKarger to check if you already have access to this title.